
    
      DNDI-0690 is intended to be used as oral treatment for Visceral Leishmaniasis with potential
      for the cutaneous form of the disease, Cutaneous Leishmaniasis. The present protocol
      describes the first-in-human (FIH) study with DNDI-0690.
    
  